Clinical Research Directory

Inclusion Criteria: * The child is between the ages of 7 to 17 years inclusive at enrollment. * The child has clinically significant symptoms of anxiety and/or OCD, as indicated by a score of 12 or higher on the Pediatric Anxiety Rating Scale (PARS). * The child is appropriate for anxiety-focused treatment (e.g., anxiety or OCD is the primary or co-primary problem as diagnosed using the DIAMOND-KID). * One parent/guardian is able and willing to participate in assessment and treatment (e.g., has sufficient English fluency, the decisional capacity to participate, and can commit to treatment duration). * The participating parent/guardian lives with their child at least 50% of the time per self-report. * Both parent and child can read and understand English. * The participant has an IQ above 69, based on the KBIT-2, another valid test or clinician judgement (e.g., a previous assessment conducted, and report shared with study team). * Participants must be in the state of Texas for treatment sessions/assessments. Exclusion Criteria: * The child has a diagnosis of a lifetime psychotic disorder and/or conduct disorder. * The child has significant, current and active suicidality/homicidality and/or self-injury requiring medical intervention. * The child has limited verbal communication abilities (e.g., no independent verbal communication). * The child is receiving concurrent psychotherapy with anxiety and/or OCD as the primary focus. They can pause ongoing therapy to enroll. * The child has initiated new antidepressant medication within 12-weeks of assessment (4-weeks for stimulants/benzodiazepines/antipsychotics) or during therapy. * The child has changed psychotropic medication dosage within 4-weeks of assessment (2-weeks for stimulants/benzodiazepines/antipsychotics) or during therapy. * The child requires a higher level of care than can be provided through the study (e.g., significant, current suicidal ideation).